rs12368672 — STAT6 STAT6 intronic variant

Deep intronic variant in STAT6 that modulates IL-4/IL-13 signal transduction; the G allele is associated with eosinophilic esophagitis relapse on proton pump inhibitor therapy and with altered eosinophil recruitment in atopic inflammation, likely through effects on STAT6 expression or splicing in Th2-activated tissue

See your personal result for STAT6

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

STAT6 Intronic Variant — When the Signal Transducer Can't Brake the Th2 Response

STAT611 STAT6
Signal Transducer and Activator of Transcription 6 — the transcription factor activated downstream of both IL-4 and IL-13 receptor signaling, translating Th2 cytokine input into gene expression changes in target tissues sits at the convergence of the allergic inflammation circuit. When IL-4 or IL-13 binds their shared receptor subunit (IL-4Rα), JAK kinases phosphorylate STAT6, enabling it to dimerize and translocate to the nucleus, where it drives expression of IgE class-switching factors, mucus genes, and eosinophil-recruiting chemokines. Every atopic tissue — asthmatic airways, eczematous skin, inflamed esophageal epithelium — shows STAT6 activation as a central event.

The rs12368672 variant lies deep within an intron of STAT6 on chromosome 12q13.3, roughly 18 kb into the gene's reference sequence. The C allele is ancestral and more common (~68% globally); the G allele reaches highest frequency in Europeans (~40%) and lowest in Africans (~18%). Three STAT6 intronic variants — rs324011, rs167769, and rs12368672 — form a tight linkage disequilibrium block (r² ≥ 0.80), meaning they are typically inherited together as a haplotype and studies of any one serve as proxies for the others.

The Mechanism

As a deep intronic variant, rs12368672 does not alter the STAT6 protein sequence. Its most likely functional modes are [cis-regulatory | affecting gene expression from the same chromosome copy] — influencing STAT6 transcription levels, pre-mRNA splicing efficiency, or RNA stability in specific tissues. In tissues activated by IL-13 (esophageal epithelium, bronchial mucosa, intestinal epithelium), even modest differences in STAT6 expression or transcript processing could alter the gain of the IL-4/IL-13 → STAT6 signaling axis. The closely linked rs324013 variant in the same STAT6 LD block has been shown by electrophoretic mobility shift assay to affect transcription factor binding at its locus22 affect transcription factor binding at its locus
He et al., Genes Immun 2008, suggesting the haplotype has genuine regulatory effects on STAT6 expression rather than being a purely neutral tag.

When STAT6 is expressed at higher levels or is more efficiently activated, the downstream consequences in Th2-activated tissues include enhanced eosinophil recruitment (via eotaxin/CCL26 upregulation), increased goblet cell mucin production, and amplified epithelial barrier disruption — the cellular substrate of eosinophilic esophagitis, atopic asthma, and atopic dermatitis.

The Evidence

The most direct evidence for rs12368672 comes from a 2021 prospective cohort study of 73 pediatric eosinophilic esophagitis patients by Mougey et al.33 2021 prospective cohort study of 73 pediatric eosinophilic esophagitis patients by Mougey et al. All three STAT6 LD-block variants (rs324011, rs167769, rs12368672) were genotyped; carriers of the G-allele haplotype faced 2.3- to 2.8-fold increased odds of EoE relapse after one year of maintenance proton pump inhibitor (PPI) therapy (OR 2.77, 95% CI 1.11–6.92 for rs324011; P = .029). Carriers also faced 2.8- to 4.1-fold increased odds of intermediate-grade tissue eosinophilia (6–14 eos/hpf, a marker of incomplete remission). This is the only study with direct genotype-outcome data for rs12368672 itself; effect sizes were consistent across all three linked variants.

A 2024 pharmacogenetic study of 28 EoE patients by Soria-Chacartegui et al.44 2024 pharmacogenetic study of 28 EoE patients by Soria-Chacartegui et al. specifically examined rs12368672 genotype and found that GG homozygotes had significantly higher baseline peak eosinophil counts compared to G/C and C/C carriers (83.2 vs 52.9 eos/hpf; P = 0.027). GG and GC genotypes showed greater EREFS symptom score reduction with omeprazole, suggesting the G allele enriches a subset of EoE patients who are more responsive to PPI-mediated STAT6 suppression — but who also relapse more rapidly without it.

For asthma, a 2023 Chinese case-control study (Zheng et al., 597 asthma cases / 632 controls) found significant differences in rs12368672 genotype and allele distributions between asthma patients and healthy controls55 2023 Chinese case-control study (Zheng et al., 597 asthma cases / 632 controls) found significant differences in rs12368672 genotype and allele distributions between asthma patients and healthy controls (P = 0.007), supporting a shared genetic susceptibility role for the STAT6 LD block across atopic airway conditions.

In the context of parasite defense, the linked rs324013 variant in the same STAT6 region showed an additive interaction with IL13 rs1800925 on urinary schistosome infection burden in an 841-person Malian cohort66 an additive interaction with IL13 rs1800925 on urinary schistosome infection burden in an 841-person Malian cohort — each variant alone was associated with infection levels, and carrying risk alleles at both loci compounded the susceptibility (additive interaction P = 0.011). This documents that the STAT6 LD block regulates Th2-mediated parasite defense as well as allergic tissue eosinophilia, two sides of the same Th2 immune coin.

Practical Actions

For G-allele carriers, the actionable implications center on the esophageal and airway phenotypes where STAT6 pathway activation drives eosinophil-mediated tissue damage. In EoE, the G allele signals elevated relapse risk on maintenance PPI therapy, making endoscopic follow-up during PPI dose reduction a specific and genotype-relevant monitoring step. For asthma or atopic disease generally, STAT6-pathway biologics (dupilumab blocks IL-4Rα upstream of STAT6; a number of downstream targets are also in development) are particularly relevant for patients with poor control.

Interactions

The primary interaction partner for this variant is [rs1800925 | IL13 -1112C>T promoter variant — the T allele increases IL-13 production in Th2 cells by disrupting a STAT6 repressor binding site and creating a Yin-Yang 1 activator site], whose risk T allele increases the ligand load on the STAT6 pathway. Carrying both the IL13 -1112T allele (more IL-13 produced) and the STAT6 G-allele haplotype (altered STAT6 expression) places both ends of the IL-13 → STAT6 signaling axis in a sensitized state. The He et al. (2008) data on schistosome infection demonstrates a statistically significant additive interaction (P = 0.011) between these variants at exactly this junction.

The [rs1801275 | IL4R Q576R (rs1801275-G) — gain-of-function variant in the IL-4Rα receptor subunit upstream of STAT6] is another relevant partner: a hyperactive IL-4Rα receptor would further amplify STAT6 signaling even if STAT6 expression is unaltered, compounding a STAT6 regulatory variant's effect.

Genotype Interpretations

What each possible genotype means for this variant.

CC Standard STAT6 Regulation Normal

Reference STAT6 intronic haplotype — typical eosinophil regulation in atopic contexts

You have two copies of the reference C allele at rs12368672, part of the common STAT6 intronic haplotype. STAT6 expression and activity in your IL-4/IL-13-responsive tissues operates at population-typical levels for this locus. About 46% of the global population shares this genotype; it is most common in African-ancestry populations (~68% CC frequency) and least common in Europeans (~36%).

CG Partial STAT6 Risk Haplotype Intermediate

One G allele — moderately elevated eosinophilic inflammation risk in atopic conditions

The STAT6 intronic LD block containing rs12368672 likely influences STAT6 expression or transcript processing in Th2-activated tissues. In the heterozygous state, one copy carries the variant intronic sequence. Pediatric EoE data (Mougey et al. 2021) found consistent risk elevation across all three linked variants, including rs12368672, with odds ratios for relapse clustering around 2.5–2.8 in G-allele carriers.

The 2024 Soria-Chacartegui study found GC heterozygotes (along with GG homozygotes) showed greater EREFS score reduction on PPI therapy, suggesting the G allele enriches an EoE subtype with active STAT6-mediated eosinophilia that responds to — but rapidly rebounds without — PPI-mediated suppression of acid-driven STAT6 activation.

GG Full STAT6 Risk Haplotype High Risk

Two G alleles — highest eosinophilic inflammation risk; EoE relapse and elevated baseline eosinophil counts on PPI therapy

With both alleles encoding the intronic G variant, all copies of your STAT6 gene in relevant tissues carry the modified intronic sequence. The mechanistic interpretation most consistent with the data is that this haplotype alters STAT6 expression or splicing efficiency in IL-13-responsive tissues (esophageal epithelium, bronchial mucosa), shifting the gain of the IL-13 → STAT6 signal transduction axis. STAT6 activation in the esophagus drives eotaxin (CCL26) production, eosinophil recruitment, and the mast cell hyperplasia that define EoE histopathology.

The GG genotype also appears in the context of the broader STAT6–IL13 interaction: the linked rs324013 variant in the same STAT6 LD block showed an additive interaction with IL13 rs1800925 on schistosome infection burden (He et al. 2008, P=0.011). For an individual who carries both the IL13 -1112T risk allele (rs1800925) and the STAT6 GG genotype, both the source of IL-13 (overproduction) and its signal transducer (potentially altered expression) are affected simultaneously.

The asthma association (Zheng et al. 2023, p=0.007) suggests the STAT6 LD block is relevant across atopic airway disease as well, consistent with the shared role of STAT6 in bronchial versus esophageal eosinophilic inflammation.